Apply for Tecfidera (Dimethyl Fumarate)
Copay Assistance | Copay Card | QuickRx

Yes, completely free. QuickRx Specialty Pharmacy provides free enrollment and support for all Tecfidera copay card programs and dimethyl fumarate copay assistance programs including manufacturer copay cards and patient assistance programs. We never charge service fees for helping patients access medication savings.

What’s included at no cost:

• Application assistance for Tecfidera manufacturer copay cards
• Generic dimethyl fumarate copay card enrollment
• Insurance verification and benefit checks
• Prior authorization support when needed
• Foundation grant applications for multiple sclerosis treatment
• Ongoing monitoring to ensure continuous savings

Tecfidera (dimethyl fumarate) savings programs available:

For patients with commercial insurance, manufacturer copay cards for Tecfidera or generic dimethyl fumarate can significantly reduce your out-of-pocket costs.

For Medicare and Medicaid patients, foundation-based assistance programs provide grants that help cover medication expenses. These programs are also free to apply for with QuickRx’s help.

For uninsured patients, the Tecfidera patient assistance program may provide dimethyl fumarate at no cost or significantly reduced prices based on financial need.

Our team’s only goal is to make Tecfidera (dimethyl fumarate) more affordable so you can focus on managing your multiple sclerosis without financial stress. Contact QuickRx at (917) 830-2525 or (800) 496-6111 to get started today.

Eligibility for Tecfidera copay assistance or dimethyl fumarate copay card programs depends on your insurance type and your financial situation. QuickRx helps determine which programs you qualify for at no cost.

Eligibility criteria for Tecfidera copay cards:

Commercial insurance patients with coverage for Tecfidera (dimethyl fumarate) typically qualify for manufacturer copay cards. Requirements usually include:

• Active commercial (private) health insurance that covers Tecfidera or dimethyl fumarate
• Valid prescription for dimethyl fumarate
• Treatment for FDA-approved indications (relapsing forms of multiple sclerosis)
• US residency

Alternative assistance for other insurance types:

Medicare and Medicaid patients cannot use manufacturer copay cards due to federal regulations, but may qualify for foundation grants and other patient assistance programs specifically designed for government insurance beneficiaries.

Uninsured patients may qualify for the Tecfidera patient assistance program that provides free or low-cost dimethyl fumarate based on household income and financial need.

How QuickRx determines your eligibility:

When you contact QuickRx, we review your insurance coverage, prescription details, and financial situation to identify every Tecfidera (dimethyl fumarate) assistance program you qualify for. We then handle all applications and enrollment paperwork on your behalf.

Call (917) 830-2525 or (800) 496-6111 to speak with a copay assistance specialist who can verify your eligibility for Tecfidera copay card and dimethyl fumarate savings programs today.

Savings vary by insurance type and the assistance programs you qualify for. QuickRx works to maximize your savings through all available Tecfidera copay assistance programs.

Potential Tecfidera (dimethyl fumarate) copay assistance savings:

With commercial insurance, manufacturer copay cards can reduce your Tecfidera copay to as low as $0-$50 per prescription. Annual savings limits typically range from $12,000-$15,000.

With Medicare or Medicaid, foundation grants and patient assistance programs help cover medication costs that Medicare doesn’t pay. Grant amounts vary by foundation and availability of funds.

For uninsured patients, the Tecfidera patient assistance program may provide dimethyl fumarate at no cost if you meet income eligibility requirements.

Why savings amounts vary:

Without assistance, Tecfidera (dimethyl fumarate) can cost $6,000-$7,500 per month. Your actual savings depend on:

• Your insurance plan’s coverage and cost-sharing structure
• Whether you receive brand Tecfidera or generic dimethyl fumarate
• Annual benefit caps on copay assistance programs
• Foundation funding availability at the time of application
• Your household income (for patient assistance programs)

Contact QuickRx at (917) 830-2525 or (800) 496-6111 to find out exactly how much you can save on your Tecfidera or dimethyl fumarate medication.

Yes, Medicare patients can access Tecfidera (dimethyl fumarate) financial assistance, but not through manufacturer copay cards. Medicare beneficiaries may qualify for foundation grants and other patient assistance programs specifically designed to help cover out-of-pocket costs for MS medications.

Why Medicare patients can’t use Tecfidera copay cards:

Federal anti-kickback laws prohibit pharmaceutical manufacturers from offering copay cards to Medicare and Medicaid beneficiaries. This applies to both brand Tecfidera and generic dimethyl fumarate copay cards.

Alternative assistance for Medicare patients:

QuickRx connects Medicare patients with alternative Tecfidera copay assistance programs including:

• Independent charitable foundations that provide grants for MS medications
• Disease-specific foundations focused on multiple sclerosis
• The Tecfidera patient assistance program for qualifying patients
• State pharmaceutical assistance programs (SPAPs) where available

How QuickRx helps Medicare patients:

Our team specializes in navigating the complex landscape of Medicare Part D coverage for specialty medications like Tecfidera (dimethyl fumarate). We help you:

• Understand your Medicare Part D plan’s coverage for dimethyl fumarate
• Apply for foundation grants to cover copays, coinsurance, and deductibles
• Navigate the Medicare donut hole (coverage gap)
• Complete patient assistance program applications if you qualify

Don’t let Medicare restrictions prevent you from affording your Tecfidera medication.

If you’re struggling to afford Tecfidera (dimethyl fumarate), QuickRx Specialty Pharmacy can help you access financial assistance programs regardless of your insurance situation. We specialize in finding solutions for patients who cannot afford their multiple sclerosis medications.

Financial assistance options by insurance type:

With commercial insurance:

• Tecfidera copay card programs
• Generic dimethyl fumarate copay assistance
• Disease-specific foundation grants for multiple sclerosis

With Medicare or Medicaid:

• Independent charitable foundation grants
• State pharmaceutical assistance programs
• Tecfidera patient assistance program (if eligible)
• Medicare Extra Help/Low-Income Subsidy programs

Without insurance:

• Tecfidera patient assistance program providing free medication
• Foundation grants for uninsured patients
• Assistance finding affordable insurance coverage

Emergency medication access:

If you need your Tecfidera (dimethyl fumarate) medication urgently and cannot afford it, contact QuickRx immediately. We can often expedite applications for emergency assistance programs to ensure you don’t miss doses of your critical medication.

Tecfidera (dimethyl fumarate) is a prescription medication approved by the FDA in March 2013 for treating relapsing forms of multiple sclerosis (MS) in adults. It is taken as an oral capsule twice daily.

How Tecfidera works:

Dimethyl fumarate is classified as an Nrf2 activator. It works through multiple mechanisms:

• Activates the Nrf2 pathway, which helps protect cells from oxidative stress and inflammation
• Reduces inflammation in the central nervous system
• May provide neuroprotective effects to help preserve nerve function
• Modifies the immune response to reduce attacks on the myelin sheath

Proven effectiveness:

Clinical studies have demonstrated that Tecfidera (dimethyl fumarate):

• Reduces annual relapse rates by approximately 49% compared to placebo
• Decreases risk of disability progression by approximately 38%
• Significantly reduces new or enlarging brain lesions on MRI
• Shows consistent benefits with long-term use

Tecfidera is not a cure for MS but is considered a disease-modifying therapy that helps slow disease progression and reduce relapse frequency.

For help affording Tecfidera (dimethyl fumarate), contact QuickRx at (917) 830-2525 or (800) 496-6111.

Tecfidera (dimethyl fumarate) is FDA-approved specifically for treating relapsing forms of multiple sclerosis in adults.

Approved uses of Tecfidera:

Clinically Isolated Syndrome (CIS): A first episode of neurological symptoms caused by inflammation and demyelination in the central nervous system that lasts at least 24 hours. CIS may be the first sign of MS.

Relapsing-Remitting MS (RRMS): The most common form of MS, characterized by clearly defined attacks (relapses) of worsening neurological function followed by periods of partial or complete recovery (remission).

Active Secondary Progressive MS: A form of MS that initially follows a relapsing-remitting course but then transitions to gradual worsening of symptoms with or without occasional relapses.

What is multiple sclerosis:

Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system (brain and spinal cord). In MS, the immune system attacks the protective myelin sheath covering nerve fibers, disrupting communication between the brain and body. Common symptoms include:

• Vision problems
• Numbness or weakness in limbs
• Tingling or pain
• Fatigue
• Difficulty with coordination and balance
• Cognitive changes

Starting treatment with a disease-modifying therapy like Tecfidera (dimethyl fumarate) early in the course of MS can reduce the frequency and severity of relapses and slow disability progression.

We believe that high deductibles and copays shouldn’t prevent anyone from receiving the medications they need. That’s why at QuickRx, we help patients register with various public non-profit foundations and drug manufacturer programs to reduce the copays and out-of-pocket costs for the medication.

Tecfidera (dimethyl fumarate) is taken as an oral capsule twice daily. Following proper dosing instructions ensures optimal effectiveness and helps minimize side effects.

Standard dosing:

• Starting dose (Week 1): 120 mg twice daily
• Maintenance dose (Week 2 and beyond): 240 mg twice daily

How to take Tecfidera:

• Take with food: Taking Tecfidera with food may reduce flushing and GI side effects
• Swallow whole: Do not crush, chew, or open the capsules
• Take at the same times each day: Approximately 12 hours apart for best results
• Aspirin tip: Taking a non-enteric coated aspirin (325 mg or less) 30 minutes before Tecfidera may help reduce flushing

If you miss a dose:

• Take it as soon as you remember
• If it’s almost time for your next dose, skip the missed dose
• Do NOT take two doses at once to make up for a missed dose

Contact QuickRx Specialty Pharmacy if you have questions about taking Tecfidera (dimethyl fumarate) or need refill reminders.

Like all medications, Tecfidera (dimethyl fumarate) can cause side effects. Most patients tolerate it well, but it’s important to recognize potential problems early.

Common side effects:

These side effects are typically mild and often improve over time:

• Flushing: Warmth, redness, itching, or burning feeling of the skin (especially face and neck)
• Gastrointestinal issues: Nausea, diarrhea, abdominal pain, vomiting
• Decreased appetite

Serious side effects requiring immediate medical attention:

Allergic reactions: Difficulty breathing, hives, swelling of the throat or tongue

PML (Progressive Multifocal Leukoencephalopathy): A rare but serious brain infection. Symptoms include progressive weakness, vision changes, confusion, memory problems, personality changes

Decreased white blood cell count (lymphopenia): Can increase risk of infections. Your doctor will monitor blood counts regularly

Liver problems: Yellowing of skin/eyes, dark urine, severe nausea, pain in upper right abdomen

Herpes zoster infections (shingles): Painful skin rash with blisters

Monitoring requirements:

Your doctor will monitor you regularly with:

• Complete blood counts (CBC) including lymphocyte counts before starting and every 3 months
• Liver function tests before starting and as clinically indicated
• Regular neurological assessments

Report any unusual symptoms to your doctor promptly. For 24/7 pharmacist support, call QuickRx at (917) 830-2525 or (800) 496-6111.

Tecfidera (dimethyl fumarate) has several important drug interactions. Always inform your healthcare providers about all medications you’re taking.

Contraindicated medications (DO NOT combine):

Diroximel fumarate (Vumerity): Risk X: Avoid combination. Both contain the same active metabolite (monomethyl fumarate), which can increase adverse/toxic effects.

Monomethyl fumarate: Risk X: Avoid combination. May increase adverse/toxic effects of dimethyl fumarate.

Medications requiring caution:

Live vaccines: Dimethyl fumarate may increase the risk of vaccine-associated infection and decrease the therapeutic effects of live vaccines. Non-US labeling states that live attenuated vaccines are not recommended during treatment.

Other immunosuppressants: Combining with other immune-suppressing medications may increase infection risk.

What to discuss with your doctor:

• Complete list of current medications
• Any planned vaccinations
• Over-the-counter medications, vitamins, and supplements
• History of previous MS therapies

QuickRx pharmacists provide comprehensive drug interaction screening for all Tecfidera (dimethyl fumarate) patients.

Tecfidera (dimethyl fumarate) is contraindicated in certain patients. Your doctor will determine if it’s safe for you.

Do NOT take Tecfidera if:

• Known hypersensitivity: Severe allergic reactions to dimethyl fumarate or diroximel fumarate (Vumerity)
• Currently taking: Diroximel fumarate (Vumerity) or monomethyl fumarate

Use with caution if you have:

• Low white blood cell counts: Lymphopenia increases infection risk
• Active infections: Treatment should be delayed until infections resolve
• Liver disease: Liver function monitoring required

Pregnancy and breastfeeding:

• Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding
• A pregnancy registry exists to monitor outcomes in women who take dimethyl fumarate during pregnancy
• The decision to use Tecfidera during pregnancy should weigh potential benefits against risks

Age considerations:

• Tecfidera is approved for adults only
• Not approved for use in patients under 18 years old

For confidential consultation about whether Tecfidera (dimethyl fumarate) is appropriate for your situation, call QuickRx specialty pharmacists at (917) 830-2525 or (800) 496-6111.

Yes, generic dimethyl fumarate is available. QuickRx Specialty Pharmacy dispenses both brand-name Tecfidera and generic dimethyl fumarate, helping you access copay assistance for whichever version your insurance covers.

Brand-name Tecfidera:

• Manufactured by Biogen
• Original FDA-approved version (March 2013)
• Manufacturer copay assistance programs available
• Available in 120 mg and 240 mg capsules

Generic dimethyl fumarate:

• Multiple FDA-approved generic manufacturers
• Contains same active ingredient (dimethyl fumarate)
• Same strengths (120 mg and 240 mg)
• FDA-determined therapeutic equivalence to brand Tecfidera
• Often lower baseline cost than brand

Copay assistance for both versions:

QuickRx helps patients access copay assistance for both brand Tecfidera and generic dimethyl fumarate:

• Brand Tecfidera: Manufacturer copay card programs may reduce costs to $0-$50/month
• Generic dimethyl fumarate: Dimethyl fumarate copay card programs and foundation assistance available

Tecfidera (dimethyl fumarate) begins affecting the immune system within days of starting treatment, but clinical benefits typically take several months to become measurable.

Timeline for Tecfidera effectiveness:

Immediate effects (Days to weeks):

• Dimethyl fumarate starts affecting immune cell activity within the first few weeks
• Anti-inflammatory effects begin immediately
• Not noticeable to patients

Clinical benefits (2-6 months):

• Reduction in relapse rates becomes measurable over several months
• Clinical studies showed significant benefits at 2-year mark
• Individual response varies

MRI improvements (6-12 months):

• Reductions in new or enlarging brain lesions typically observed at follow-up scans
• Decreased gadolinium-enhancing lesions

Important expectations:

Tecfidera is preventive, not symptomatic treatment:

• Goal is to reduce future relapses and slow MS progression
• Does not reverse existing damage or eliminate current symptoms
• Works by preventing new disease activity

Take Tecfidera (dimethyl fumarate) exactly as prescribed even if you don’t notice immediate changes. Benefits accumulate over time with continuous use.

Yes, Tecfidera (dimethyl fumarate) requires regular medical monitoring to ensure safety and effectiveness.

Before starting treatment:

• Complete blood count (CBC) including lymphocyte counts
• Liver function tests (transaminases, alkaline phosphatase, total bilirubin)
• Assessment for active infections
• Pregnancy test (if applicable)

During treatment:

• CBC with lymphocyte counts: Every 3 months after starting therapy, then as clinically necessary
• For patients with lymphopenia: Monitor until resolution
• Grade 3 lymphopenia: Monitor more frequently at intervals less than 3 months
• Signs of infection: Especially in patients with lower lymphocyte counts
• Liver function tests: Prior to treatment initiation and during treatment as clinically indicated
• Urinalysis: If proteinuria suspected and/or clinically indicated
• MRI: Baseline and as clinically indicated to monitor for progressive multifocal leukoencephalopathy (PML)

Why monitoring is important:

Regular monitoring helps detect:

• Lymphopenia (low lymphocyte counts) that may increase infection risk
• Liver enzyme elevations
• Early signs of PML (rare but serious brain infection)
• Other potential complications

Your healthcare provider will determine the appropriate monitoring schedule based on your individual needs.

While taking Tecfidera (dimethyl fumarate), you should avoid or be cautious with certain medications and activities.

Medications to avoid:

• Diroximel fumarate (Vumerity): Never take together – same active metabolite
• Monomethyl fumarate: Avoid combination

Live vaccines:

• Live attenuated vaccines are not recommended during treatment (per non-US labeling)
• Safety and effectiveness of live vaccines with dimethyl fumarate has not been assessed (US labeling)
• Talk to your doctor about necessary vaccinations before starting treatment

Alcohol considerations:

• Alcohol may worsen flushing side effects
• Discuss alcohol use with your healthcare provider

Situations requiring caution:

• Infections: Contact your doctor if you develop signs of infection
• Pregnancy: Discuss with your doctor if planning to become pregnant
• Surgery: Inform surgical teams about your Tecfidera use

Always consult your healthcare provider before starting any new medications while taking Tecfidera (dimethyl fumarate). For questions, call QuickRx at (917) 830-2525 or (800) 496-6111.

For comprehensive medical information about Tecfidera (dimethyl fumarate), consult these trusted resources:

• Tecfidera Official Website – Patient information and support resources
• Tecfidera Prescribing Information – Official FDA-approved drug information
• UpToDate – Evidence-based clinical resource for healthcare professionals
• MedlinePlus – Dimethyl Fumarate – Consumer health information from the National Library of Medicine
• National Multiple Sclerosis Society – MS education and support resources

For questions about Tecfidera (dimethyl fumarate) copay assistance or prescription access, contact QuickRx Specialty Pharmacy at (800) 496-6111.

References

1. Tecfidera (dimethyl fumarate) [prescribing information]. Cambridge, MA: Biogen Inc; December 2023.
2. Dimethyl Fumarate: Drug information. UpToDate Lexi-Drugs. Accessed November 2025.
3. FDA Approval: March 27, 2013.
4. National Multiple Sclerosis Society. MS Treatment Information. Accessed November 2025.
5. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788.